Berotralstat

(Orladeyo®)

Orladeyo®

Drug updated on 11/15/2023

Dosage FormCapsule (oral: 110 mg, 150 mg)
Drug ClassPlasma kallikrein inhibitors
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients.

Product Monograph / Prescribing Information

Document TitleYearSource
Orladeyo (berotralstat) Prescribing Information.2022BioCryst Pharmaceuticals, Inc., Durham, NC

Systematic Reviews / Meta-Analyses